Maxiflo Inhaler 125 Mcg (Fluticasone & Formoterol)

Maxiflo Inhaler 125 mcg – Effective Mid-Range Combination Therapy

For patients navigating the critical middle ground of asthma management — where low-dose combination therapy no longer delivers adequate control but maximum-strength formulations are not yet clinically warranted — Maxiflo Inhaler 125 mcg occupies a uniquely valuable therapeutic position. Delivering fluticasone propionate 125mcg and formoterol fumarate 6mcg per actuation through a compact, familiar pressurised metered dose inhaler, Maxiflo 125mcg provides genuinely meaningful mid-range anti-inflammatory coverage alongside the fast-onset, sustained bronchodilation that formoterol’s distinctive pharmacological profile uniquely offers — in a single, twice-daily aerosol inhalation that addresses both the inflammatory and bronchospastic dimensions of airway disease simultaneously.

Manufactured by Mankind Pharma — one of India’s fastest growing and most widely recognised pharmaceutical companies — Maxiflo Inhaler 125mcg offers patients a high-quality, affordable mid-strength ICS-formoterol pMDI combination at a price point that supports consistent long-term treatment adherence without compromise. At our online pharmacy, we stock genuine Maxiflo Inhaler 125 mcg products, giving patients convenient, discreet, and affordable access to this clinically well-positioned combination respiratory therapy.

What Is Maxiflo Inhaler 125 mcg?

Maxiflo Inhaler 125 mcg is a fixed-dose combination pressurised metered dose inhaler (pMDI) containing fluticasone propionate 125mcg and formoterol fumarate 6mcg per actuation, manufactured by Mankind Pharma and delivered through a hydrofluorocarbon propellant aerosol system in a compact pressurised inhaler canister.

The 125mcg fluticasone dose positions Maxiflo Inhaler 125 mcg as a mid-range option within the Maxiflo Inhaler product family — sitting between the entry-level Maxiflo 50mcg and the higher-strength Maxiflo 250mcg formulations. This mid-range positioning serves the clinically important patient group requiring more meaningful corticosteroid anti-inflammatory coverage than low-dose products provide, while not yet requiring escalation to the full mid-strength 250mcg dose — making Maxiflo 125mcg a practically important intermediate step in combination therapy dose titration.

What distinctively sets Maxiflo Inhaler 125 mcg apart from many other mid-range combination inhalers is its formoterol LABA component — providing rapid bronchodilator onset within one to three minutes alongside sustained twelve-hour duration. This fast-onset profile is clinically unique among long-acting bronchodilators and distinguishes Maxiflo from salmeterol-containing competitors at equivalent fluticasone dose strengths — offering patients both maintenance protection and immediate bronchodilator reassurance from a single combination device.

As a pMDI format, Maxiflo Inhaler 125 mcg is fully compatible with valved holding chamber spacer devices — an important clinical advantage that improves drug delivery efficiency, reduces oropharyngeal corticosteroid deposition, and makes effective dosing accessible for patients who benefit from spacer-assisted delivery.

How Maxiflo Inhaler 125 mcg Works?

Maxiflo Inhaler 125 mcg delivers two pharmacologically complementary active ingredients whose combined therapeutic action addresses chronic airway disease more comprehensively than either component could achieve independently — and does so through mechanisms that interact synergistically at the molecular level.

Fluticasone Propionate 125mcg — Intermediate-Dose ICS Anti-inflammatory Protection

At the 125mcg intermediate dose, fluticasone propionate delivers meaningfully stronger anti-inflammatory airway protection than low-dose 50mcg products while providing a measured, clinically appropriate intermediate step before the higher 250mcg strength for patients whose disease warrants dose escalation but not maximum mid-strength coverage.

Fluticasone’s extraordinary glucocorticoid receptor binding affinity — significantly higher than budesonide and beclomethasone — ensures that even at the 125mcg intermediate dose, its suppression of the airway inflammatory cascade is comprehensive and clinically significant. It simultaneously inhibits eosinophil and mast cell recruitment, reduces cytokine and mediator release, decreases mucosal oedema, and progressively suppresses the bronchial hyperresponsiveness driving persistent asthma symptoms.

With consistent twice-daily use, 125mcg fluticasone builds meaningful cumulative anti-inflammatory airway protection — reducing trigger sensitivity, decreasing the frequency and severity of acute exacerbations, and progressively improving the overall inflammatory baseline that supports long-term disease control and quality of life enhancement.

Fluticasone’s high lipophilicity localises the active molecule within the airway tissue after inhalation — creating a sustained local depot that prolongs anti-inflammatory action between doses while minimising systemic corticosteroid absorption. At the 125mcg intermediate dose, this pharmacokinetic profile delivers intermediate clinical anti-inflammatory efficacy with a systemic safety profile appropriate for long-term maintenance use.

Formoterol Fumarate 6mcg — Fast-Onset Twelve-Hour LABA Bronchodilation

Formoterol fumarate provides the bronchodilating component of Maxiflo Inhaler 125mcg — and does so through a pharmacological profile that is genuinely distinctive within the LABA class.

Most long-acting bronchodilators — particularly salmeterol — sacrifice rapid onset for extended duration. Formoterol does not make this trade-off. Its molecular mechanism of beta-2 receptor engagement produces bronchodilation that begins within one to three minutes of inhalation — approaching the speed of short-acting rescue bronchodilators — while simultaneously maintaining its airway-relaxing effect for a full twelve hours through persistent receptor interaction.

This dual temporal characteristic means formoterol in Maxiflo Inhaler 125mcg provides patients with immediate bronchodilator relief with every morning and evening dose — widening airways rapidly from the moment each dose is inhaled — while also sustaining that widening throughout the complete twelve-hour dosing interval. Patients experience both the reassurance of fast-acting airway opening and the security of continuous maintenance protection from a single twice-daily inhalation.

At the 6mcg dose, formoterol activates beta-2 receptors in bronchial smooth muscle — triggering cyclic AMP accumulation and smooth muscle relaxation that reduces airflow resistance, improves breathing comfort, enhances exercise tolerance, and prevents the nocturnal bronchoconstriction that disrupts sleep and dominates early morning symptom burden in asthma and COPD patients.

Read Our Asthma Inhaler Guide:- Asthma Inhalers: Types, Uses, Benefits & Complete Treatment Guide.

Maxiflo Inhaler 125 mcg vs Other Combination pMDI Options

Conditions Treated with Maxiflo Inhaler 125 mcg

Maxiflo Inhaler 125 mcg is prescribed for respiratory conditions where intermediate-dose combined ICS-formoterol therapy delivers clinically meaningful and sustained improvements in disease control:

• Mild-to-Moderate Persistent Asthma Requiring Dose Escalation — Patients on low-dose combination therapy whose symptoms remain inadequately controlled — 125mcg fluticasone provides a meaningful intermediate-dose anti-inflammatory step-up within the familiar Maxiflo pMDI format
• Moderate Persistent Asthma — Patients with moderate persistent asthma whose disease burden warrants intermediate-dose ICS coverage combined with fast-onset LABA bronchodilation
• Step-Up from Maxiflo 50mcg or Equivalent Low-Dose Combination — The natural dose progression within the Maxiflo Inhaler range for patients outgrowing entry-level combination therapy
• COPD with Inflammatory Component — COPD patients with significant eosinophilic inflammation, overlapping asthma features, or frequent exacerbations benefiting from combined anti-inflammatory and bronchodilator maintenance therapy
• Nocturnal Asthma — Formoterol’s twelve-hour coverage combined with intermediate-dose fluticasone provides effective overnight airway protection — reducing night-time coughing and early morning breathlessness
• Exercise-Induced Bronchoconstriction in Moderate Asthma — Regular twice-daily use prevents physical activity from triggering acute airway narrowing — with formoterol’s fast onset providing additional immediate bronchodilator reassurance around exercise sessions
• Patients Requiring Spacer-Compatible ICS-LABA pMDI — The pMDI format with full spacer compatibility makes Maxiflo 125mcg particularly accessible for patients who benefit from or require spacer-assisted drug delivery at intermediate ICS dose strength

Benefits of Maxiflo Inhaler 125 mcg:-

• Intermediate fluticasone dose occupying a clinically important therapeutic niche — 125mcg provides meaningful anti-inflammatory step-up beyond low-dose products without requiring immediate escalation to full mid-strength 250mcg coverage
• Formoterol’s uniquely rapid onset at intermediate ICS strength — Fast one-to-three-minute bronchodilation onset unavailable from salmeterol-based competitors at equivalent fluticasone doses
• Sustained twelve-hour dual-component coverage — Both anti-inflammatory and bronchodilator protection are maintained continuously throughout the complete twice-daily dosing cycle
• SMART therapy compatibility potential — Formoterol-based combination — potentially eligible for maintenance and reliever regimens under appropriate prescriber guidance
• Spacer device compatibility — Full pMDI spacer compatibility significantly improves drug delivery efficiency and reduces oropharyngeal deposition — a clinically important advantage over DPI formats
• Molecular synergy between fluticasone and formoterol — Each component enhances the other’s therapeutic effectiveness at the receptor level
• Familiar pMDI format — The pressurised aerosol inhaler format is the most globally recognised respiratory device, requiring minimal new learning
• Mankind Pharma pharmaceutical quality — Consistent manufacturing standards ensuring reliable potency and dose accuracy
• Affordable intermediate-strength combination — Quality ICS-formoterol combination at accessible pricing supporting consistent adherence

How to Use Maxiflo Inhaler 125 mcg?

Without a Spacer:

1. Remove the mouthpiece cap — Remove and inspect the mouthpiece for debris before every use
2. Shake vigorously — Shake the Maxiflo Inhaler firmly for five full seconds before every actuation — ensuring uniform medication dispersion throughout the propellant
3. Prime if necessary — Release two to three test actuations into the air if using a new inhaler or one unused for more than five days
4. Breathe out fully — Exhale slowly and completely away from the mouthpiece — never exhale into the device
5. Seal and position — Place the mouthpiece between your teeth, seal your lips firmly around it, and hold the inhaler upright with the canister on top
6. Press and inhale simultaneously — Begin inhaling slowly and steadily through your mouth while pressing the canister down firmly once at the very start of inhalation
7. Continue inhaling deeply — Keep breathing in slowly and as deeply as possible after the canister press
8. Hold your breath — Remove the inhaler and hold breath for ten full seconds before exhaling slowly
9. Replace the cap — Always replace the mouthpiece cap immediately after every use
10. Rinse your mouth — Always rinse thoroughly with water and spit immediately after every dose

With a Spacer:

1. Attach the Maxiflo Inhaler 125mcg firmly to the spacer inlet connection
2. Shake the assembled inhaler and spacer vigorously for five seconds
3. Breathe out gently and completely away from the spacer mouthpiece
4. Place lips firmly around the spacer mouthpiece forming a complete seal
5. Press the Maxiflo canister once to release the dose into the spacer chamber
6. Inhale slowly and deeply through the spacer mouthpiece
7. Hold breath for ten seconds before exhaling slowly
8. Rinse mouth with water and spit after completion

Important Usage Information

Twice Daily Without Fail — Maxiflo Inhaler 125 mcg must be taken consistently at twelve-hour intervals every single day. Fluticasone’s anti-inflammatory benefit depends entirely on uninterrupted regular use — even brief periods of missed doses allow airway inflammation to return progressively.

Formoterol Is Not a Conventional Short-Acting Rescue Bronchodilator — Despite formoterol’s rapid onset, Maxiflo Inhaler 125 mcg is a combination maintenance medication. Unless specifically prescribed under a SMART therapy regimen by your doctor, always keep a separate short-acting salbutamol reliever inhaler available for sudden acute breathlessness or emergency use.

Use a Spacer Where Appropriate — Spacer use with Maxiflo Inhaler 125 mcg significantly improves lower airway drug deposition, reduces oropharyngeal fluticasone deposition and associated oral thrush risk, and is particularly recommended for patients who have previously experienced inhaler coordination difficulties or corticosteroid-related local side effects.

Mouth Rinsing Is Non-Optional — Always rinse thoroughly with water and spit after every Maxiflo Inhaler 125 mcg dose — at the intermediate 125mcg fluticasone dose, the risk of oral thrush and hoarseness from oropharyngeal corticosteroid deposition requires consistent mouth rinsing after every single inhalation.

Shake Before Every Actuation — Unlike DPI devices, the pMDI requires vigorous shaking before each use to ensure accurate, uniform dose composition — never skip the pre-dose shake.

Report Deteriorating Control Promptly — If asthma control worsens despite consistent twice-daily Maxiflo 125 mcg use, contact your prescriber without delay — stepping up to Maxiflo 250mcg or alternative therapy may be clinically warranted.

Frequently Asked Questions?

What is Maxiflo Inhaler 125 mcg used for?

Maxiflo Inhaler 125 mcg delivers intermediate-dose combined fluticasone and formoterol therapy for mild-to-moderate persistent asthma and COPD — providing dual anti-inflammatory and fast-onset bronchodilator control through a twice-daily pressurised metered dose inhaler.

How does Maxiflo 125 mcg differ from Seretide 125mcg Evohaler?

Both contain fluticasone 125 mcg but differ in their LABA component. Maxiflo contains formoterol with a fast onset of one to three minutes while Seretide Evohaler contains salmeterol with a slower fifteen-to-thirty-minute onset. Formoterol’s rapid onset gives Maxiflo an immediate bronchodilator advantage that salmeterol-based products cannot offer.

Should I use a spacer with the Maxiflo Inhaler 125 mcg?

Using a spacer with the Maxiflo Inhaler 125 mcg is strongly recommended where beneficial — improving drug delivery efficiency, reducing oral thrush risk from fluticasone deposition, and making effective dosing accessible for patients with coordination difficulties.

Can the Maxiflo Inhaler 125 mcg be used as a rescue inhaler?

While formoterol provides rapid bronchodilation, Maxiflo is primarily a maintenance medication. Unless specifically prescribed under a SMART regimen, always maintain a separate salbutamol rescue inhaler for acute emergency use.

When should I step up from Maxiflo 125 mcg to 250 mcg?

If asthma remains inadequately controlled despite consistent twice-daily Maxiflo 125mcg use, consult your prescriber — the 250mcg strength may be clinically indicated based on your individual disease assessment.

How quickly does Maxiflo Inhaler 125 mcg start working?

Formoterol begins bronchodilating within one to three minutes of each inhalation. Fluticasone’s full cumulative anti-inflammatory benefit builds progressively over days to weeks of consistent twice-daily use.

Medical Disclaimer:-

The information provided on this page is for general informational purposes only and does not constitute medical advice, a clinical diagnosis, or a personalised treatment recommendation. Maxiflo Inhaler 125 mcg is a prescription-only medication and must always be used under the direct guidance and supervision of a qualified healthcare professional. If you experience worsening respiratory symptoms, inadequate symptom control, or any unexpected side effects while using Maxiflo Inhaler 125 mcg, please consult your doctor, respiratory specialist, or pharmacist without delay. Never adjust, discontinue, or substitute your prescribed combination inhaler therapy without first obtaining appropriate professional medical advice.

Similar Brands:-

Maxiflo Rotacaps 250 Mcg (Fluticasone & Formoterol)

Duova Inhaler (Tiotropium Bromide & Formoterol)